---
title: "Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus"
id: "clinicaltrials-nct05969496"
canonical_url: "https://medichelpline.com/clinical-feed/clinicaltrials-nct05969496"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "ClinicalTrials.gov"
source_url: "https://clinicaltrials.gov/study/NCT05969496"
doi: "NCT05969496"
published_at: "2026-04-13T12:00:00.000Z"
evidence_level: "INTERVENTIONAL Trial"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/clinicaltrials-nct05969496
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** ClinicalTrials.gov
- **Source URL:** [Original Journal Publication](https://clinicaltrials.gov/study/NCT05969496)
- **DOI:** [NCT05969496](https://doi.org/NCT05969496)
- **Published At:** 2026-04-13T12:00:00.000Z
- **Evidence Rating:** INTERVENTIONAL Trial
## Executive GIST (TL;DR)
RECRUITING · INTERVENTIONAL · TREATMENT study · Renal Cancer · Phase 2 · Enrollment 17 · Sponsor: University of Colorado, Denver
## Clinical Analysis & Structured Key Points
Official title: Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Associated Inferior Vena Cava Tumor Thrombus (NEOPAX) Summary: The primary objective of this study is to evaluate whether the combination of Pembrolizumab and Axitinib given in the neoadjuvant setting can change the Inferior Vena Cava Tumor Thrombus burden. A decrease in the size of the tumor thrombus can potentially lead to decrease in surgical complications, improve patient related health outcomes, and improve long term outcomes such as progression free survival and overall survival. Conditions: Renal Cancer, Kidney Cancer, Renal Cell Carcinoma, Inferior Vena Cava Thrombosis Study type: INTERVENTIONAL Primary purpose: TREATMENT Phases: PHASE2 Enrollment: 17 (ESTIMATED) Status: RECRUITING Completion: 2029-11 (ESTIMATED)
## Related Clinical Research

- [Avoiding Cardiac Toxicity with Immune Checkpoint Inhibitors: Safety Review (Title Only Available)](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-avoidance-of-cardiac-toxicity-during-the-application-of-immune-checkpoint.md)
- [Reporting signal for interstitial pneumonitis with combined EGFR-TKI and PD-1/PD-L1 inhibitor ther](https://medichelpline.com/clinical-feed/frontiers-in-immunology-6-increased-reporting-of-interstitial-pneumonitis-with-combined-egfr-tki-and-pd-1.md)
- [mRNA vaccines vindicated: mFlusiva approval and subsequent data after HHS cancellations](https://medichelpline.com/clinical-feed/stat-news-0-opinion-one-year-since-kennedy-canceled-mrna-vaccine-projects-science-shows-how.md)
- [HPV18-Positive Cervical Large-Cell Neuroendocrine Carcinoma: Rapid Progression Despite Pembrolizum](https://medichelpline.com/clinical-feed/pubmed-42521492.md) (DOI: 10.1111/jog.70426)
- [Translational modelling questions receptor‑occupancy‑based dosing for pembrolizumab (PD‑1 inhibito](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-translational-modelling-challenges-receptor-occupancy-based-dosing-of-pd-1.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.